Analysis of PTEN deletions and mutations in multiple myeloma

被引:57
作者
Chang, H
Qi, XY
Claudio, J
Zhuang, LH
Patterson, B
Stewart, AK
机构
[1] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Dept Lab Hematol, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[3] Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Hosp, Univ Hlth Network, Toronto, ON, Canada
关键词
tumor suppressor gene; PTEN; FISH; multiple myeloma;
D O I
10.1016/j.leukres.2005.07.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clonal plasma cells from patients with multiple myeloma (MM), plasma cell leukemia (PCL) and human myeloma cell lines (HMCLs) were analyzed for deletions/mutations of the tumor suppressor gene PTEN. By interphase-FISH, hemizygous PTEN deletions were detected in 4 (5.6%) of 71 MM patients, 2 (20%) of 10 PCLs, and 2 (20%) of 10 HMCLs. PTEN deletions were detected in 4 MM patients at diagnosis with stage III disease (Durie-Salmon). Of the six cases with PTEN deletions, 1 MM had a 13q deletion, 1 PCL had a t(1 1;14), and the other PCL had a t(14;16), a 13q deletion and a p53 deletion. Sequencing analysis did not detect PTEN mutations in 11 primary MM and 5 PCL cases. Our results indicate that alterations of PTEN are uncommon in MM patients, and PTEN deletions tend to occur in advanced disease suggesting that they are secondary, rather than primary, events in the pathogenesis of MM. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:262 / 265
页数:4
相关论文
共 27 条
[21]  
2-0
[22]   P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase [J].
Myers, MP ;
Stolarov, JP ;
Eng, C ;
Li, J ;
Wang, SI ;
Wigler, MH ;
Parsons, R ;
Tonks, NK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (17) :9052-9057
[23]   PTEN gene alterations in lymphoid neoplasms [J].
Sakai, A ;
Thieblemont, C ;
Wellmann, A ;
Jaffe, ES ;
Raffeld, M .
BLOOD, 1998, 92 (09) :3410-3415
[24]   Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN [J].
Stambolic, V ;
Suzuki, A ;
de la Pompa, JL ;
Brothers, GM ;
Mirtsos, C ;
Sasaki, T ;
Ruland, J ;
Penninger, JM ;
Siderovski, DP ;
Mak, TW .
CELL, 1998, 95 (01) :29-39
[25]   Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers [J].
Steck, PA ;
Pershouse, MA ;
Jasser, SA ;
Yung, WKA ;
Lin, H ;
Ligon, AH ;
Langford, LA ;
Baumgard, ML ;
Hattier, T ;
Davis, T ;
Frye, C ;
Hu, R ;
Swedlund, B ;
Teng, DHF ;
Tavtigian, SV .
NATURE GENETICS, 1997, 15 (04) :356-362
[26]   Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway [J].
Zhang, J ;
Choi, Y ;
Mavromatis, B ;
Lichtenstein, A ;
Li, WQ .
ONCOGENE, 2003, 22 (40) :6289-6295
[27]   Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization [J].
Zojer, N ;
Königsberg, R ;
Ackermann, J ;
Fritz, E ;
Dallinger, S ;
Krömer, E ;
Kaufmann, H ;
Riedl, L ;
Gisslinger, H ;
Schreiber, S ;
Heinz, R ;
Ludwig, H ;
Huber, H ;
Drach, J .
BLOOD, 2000, 95 (06) :1925-1930